The Food Standards Agency and Food Standards Scotland have published new guidance for businesses developing cell-cultivated products and other novel foods. For small food and drink firms, the important point is simple: if a product falls into the novel food regime, it may need authorisation before it can be placed on the market.
The announcement, published on 10 July 2026, says the guidance is intended to help businesses bring products to market safely. It is aimed at firms working on cell-cultivated products and other novel foods, but the practical lesson is wider. Founders, importers, manufacturers and food brands should check the regulatory position early, before investing heavily in packaging, marketing, supply agreements or launch dates.
Novel food rules can matter to SMEs because innovation in food often starts small. A business might be testing a new ingredient, using a production method that has not been widely used in the UK, importing a product that is established elsewhere, or developing a product linked to alternative proteins. Those ideas can be commercially attractive, but they can also trigger checks around safety evidence, composition, labelling and intended use.
The new guidance should therefore be treated as a planning document, not something to read at the end of product development. A small firm that discovers late in the process that authorisation is needed can face delays, extra costs and awkward conversations with customers or investors. A firm that checks early can build the likely evidence, timings and responsibilities into its plan from the start.
There are three immediate questions for SMEs to ask. First, is the ingredient, product or process already commonly consumed in the UK, or is it new enough to need a closer look? Second, who in the supply chain is responsible for confirming the authorisation position: the manufacturer, the importer, the brand owner, or another party? Third, what evidence would be needed if the business has to make or support an application?
This matters for retailers and hospitality firms too. Even if a small business is not developing the product itself, it should understand what assurances it needs from suppliers before stocking or serving it. That is especially relevant where products are promoted as innovative, alternative, plant-based, precision-fermented, cell-cultivated or otherwise outside familiar categories.
For start-ups, the commercial risk is not only a compliance issue. A product that cannot be sold when expected can affect cashflow, launch campaigns, manufacturing slots and investor milestones. BritishSME recently covered the wider importance of testing new technology in small, measurable steps; the same discipline applies here. A food innovation project needs a regulatory checkpoint before the business commits to scale.
Small firms should also keep records of the checks they make. That does not mean building a large compliance department. It can start with a clear file showing supplier statements, product specifications, regulatory correspondence, assumptions made, and the date those assumptions were checked. If the product changes, the file should be reviewed again.
The practical takeaway is to slow down at the right moment. Food innovation can move quickly, but authorisation questions should not be left until a buyer asks for paperwork or a launch is already public. SMEs working in novel foods should read the guidance, identify whether their product is in scope, and get competent advice where the answer is unclear.
For most small businesses, the next step is not a dramatic overhaul. It is a short internal review: list any innovative ingredients or processes, confirm the regulatory status with suppliers or advisers, and make sure launch plans allow enough time for any authorisation route that may be needed.
Sources: GOV.UK announcement on new guidance for cell-cultivated and novel food businesses; GOV.UK novel foods authorisation guidance.
